-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Esophageal cancer is the seventh most common tumor in the world, with more than 500,000 deaths every year.
Checkmate577, a global, randomized, double-blind, placebo-controlled Phase 3 trial to evaluate the feasibility of the immune checkpoint inhibitor Nivolumab as a postoperative adjuvant treatment for patients with esophageal or gastroesophageal junction cancer.
immunity
The study was followed up for an average of 24.
The median disease-free survival of 532 patients in the Nivolumab treatment group was 22.
Differences in disease-free survival between groups
According to the study, for patients with esophageal cancer or gastroesophageal junction cancer who need neoadjuvant radiotherapy and chemotherapy, the adjuvant nivolumab treatment program is significantly better than placebo in terms of disease-free survival .
For patients with esophageal cancer or gastroesophageal junction cancer who need neoadjuvant chemoradiation, nivolumab adjuvant therapy is significantly better than placebo in terms of disease-free survival.
Original source:
Ronan J.
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Leave a message here
